This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vigil Neuroscience’s 8K filing here.
Vigil Neuroscience Company Profile
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Read More
- Five stocks we like better than Vigil Neuroscience
- 3 Fintech Stocks With Good 2021 Prospects
- California Resources Stock Could Be a Huge Long-Term Winner
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Manufacturing Stocks Investing
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
